Eli Lilly and Co. (NYSE:LLY) – Equities research analysts at Leerink Swann upped their FY2018 earnings per share estimates for Eli Lilly and in a research report issued to clients and investors on Thursday. Leerink Swann analyst S. Fernandez now expects that the brokerage will post earnings of $4.35 per share for the year, up from their prior estimate of $4.21. Leerink Swann currently has a “Buy” rating and a $103.00 price target on the stock. Leerink Swann also issued estimates for Eli Lilly and’s FY2019 earnings at $5.05 EPS and FY2020 earnings at $5.55 EPS.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, July 26th. The company reported $0.86 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.86. The company had revenue of $5.40 billion for the quarter, compared to analysts’ expectations of $5.14 billion. Eli Lilly and had a net margin of 11.97% and a return on equity of 23.99%. The business’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.
Several other brokerages also recently commented on LLY. Argus boosted their target price on shares of Eli Lilly and from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Tuesday, August 2nd. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $92.00 target price on the stock in a research note on Friday, August 5th. BMO Capital Markets restated an “outperform” rating and issued a $94.00 target price on shares of Eli Lilly and in a research note on Tuesday, September 27th. Goldman Sachs Group Inc. upgraded shares of Eli Lilly and from a “neutral” rating to a “buy” rating and boosted their target price for the company from $89.00 to $95.00 in a research note on Tuesday, September 27th. Finally, Credit Suisse Group AG restated a “buy” rating on shares of Eli Lilly and in a research note on Tuesday, June 28th. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $97.06.
Eli Lilly and (NYSE:LLY) opened at 82.20 on Monday. Eli Lilly and has a 52 week low of $67.88 and a 52 week high of $88.16. The stock has a 50 day moving average of $79.44 and a 200 day moving average of $77.49. The firm has a market cap of $86.94 billion, a PE ratio of 35.43 and a beta of 0.17.
A number of hedge funds have recently bought and sold shares of the company. Iowa State Bank acquired a new position in shares of Eli Lilly and during the second quarter valued at $104,000. PineBridge Investments L.P. boosted its position in shares of Eli Lilly and by 208.6% in the second quarter. PineBridge Investments L.P. now owns 1,361 shares of the company’s stock valued at $108,000 after buying an additional 920 shares in the last quarter. Cribstone Capital Management LLC acquired a new position in shares of Eli Lilly and during the second quarter valued at $117,000. Coconut Grove Bank boosted its position in shares of Eli Lilly and by 3.3% in the second quarter. Coconut Grove Bank now owns 1,550 shares of the company’s stock valued at $122,000 after buying an additional 50 shares in the last quarter. Finally, Physicians Financial Services Inc. boosted its position in shares of Eli Lilly and by 11.2% in the second quarter. Physicians Financial Services Inc. now owns 1,638 shares of the company’s stock valued at $129,000 after buying an additional 165 shares in the last quarter. 74.96% of the stock is owned by institutional investors and hedge funds.
In other Eli Lilly and news, Director Jackson P. Tai bought 5,773 shares of the stock in a transaction that occurred on Monday, August 15th. The stock was acquired at an average cost of $80.43 per share, with a total value of $464,322.39. Following the purchase, the director now owns 42,306 shares in the company, valued at $3,402,671.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Maria A. Crowe sold 2,248 shares of the stock in a transaction that occurred on Wednesday, October 5th. The stock was sold at an average price of $81.37, for a total value of $182,919.76. Following the sale, the insider now directly owns 94,319 shares of the company’s stock, valued at $7,674,737.03. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related companies with MarketBeat.com's FREE daily email newsletter.